Day One Announces Updated FIREFLY-1 Data For Tovorafenib For Relapsed or Progressive Pediatric Low-Grade Glioma, Showing Overall Response Rate Of Greater Than 50%; Median duration of tovorafenib treatment of 15.8 months
Portfolio Pulse from Benzinga Newsdesk
Day One Biopharmaceuticals has announced updated data for its FIREFLY-1 study of Tovorafenib, a treatment for relapsed or progressive pediatric low-grade glioma. The data shows an overall response rate of over 50%, with a median duration of treatment of 15.8 months.
September 11, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Day One's updated data for Tovorafenib shows promising results, which could potentially boost investor confidence and the company's stock price.
The updated data from Day One's FIREFLY-1 study shows a high response rate for Tovorafenib, a treatment for pediatric low-grade glioma. This positive news could potentially increase investor confidence in the company and lead to a rise in its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100